CAM
Cormorant Asset Management Portfolio holdings
AUM
$1.34B
This Quarter Return
+66.58%
1 Year Return
+85.27%
3 Year Return
+2,244.39%
5 Year Return
+2,846.94%
10 Year Return
+51,155.97%
AUM
$1.82B
AUM Growth
+$1.82B
(-3.4%)
Cap. Flow
+$20.8M
Cap. Flow
% of AUM
1.14%
Top 10 Holdings %
Top 10 Hldgs %
65.19%
Holding
53
New
8
Increased
7
Reduced
11
Closed
5
Top Buys
| 1 |
Praxis Precision Medicines
PRAX
|
$63.4M |
| 2 |
Janux Therapeutics
JANX
|
$56.2M |
| 3 |
DRUG
Bright Minds Biosciences
DRUG
|
$38.2M |
| 4 |
NewAmsterdam Pharma
NAMS
|
$20M |
| 5 |
OKUR
OnKure Therapeutics, Inc. Class A Common Stock
OKUR
|
$15.8M |
Top Sells
| 1 |
LBPH
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
|
$93M |
| 2 |
Vaxcyte
PCVX
|
$47.1M |
| 3 |
UroGen Pharma
URGN
|
$13.3M |
| 4 |
Biohaven
BHVN
|
$12.9M |
| 5 |
AnaptysBio
ANAB
|
$11.5M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
ALMS
26
Alumis Inc. Common Stock
ALMS
$483M
| $16.9M | 0.93% |
2,147,396
| – | – |
|
|
OKUR
27
OnKure Therapeutics, Inc. Class A Common Stock
OKUR
$38.3M
| $15.8M | 0.87% |
+1,837,739
| New | +$15.8M |
|
28
ArriVent BioPharma
AVBP
$781M
| $15.6M | 0.86% |
585,462
| – | – |
|
|
ABVX
29
Abivax
ABVX
$6.32B
| $15.6M | 0.86% |
2,130,000
| – | – |
|
30
enGene Holdings
ENGN
$249M
| $15.5M | 0.85% |
2,323,595
+1,323,595
| +132% | +$8.8M |
|
|
BIOA
31
BioAge Labs, Inc. Common Stock
BIOA
$170M
| $15.2M | 0.84% |
2,629,529
+1,000,000
| +61% | +$5.79M |
|
32
Biomea Fusion
BMEA
$114M
| $13.9M | 0.76% |
3,570,872
| – | – |
|
|
MBX
33
MBX Biosciences, Inc. Common Stock
MBX
$484M
| $12.9M | 0.71% |
700,000
| – | – |
|
|
SEPN
34
Septerna, Inc. Common Stock
SEPN
$628M
| $12.8M | 0.7% |
+560,000
| New | +$12.8M |
|
35
ImmunityBio
IBRX
$2.24B
| $7.68M | 0.42% |
+3,000,000
| New | +$7.68M |
|
36
Enliven Therapeutics
ELVN
$1.24B
| $5.63M | 0.31% |
+250,000
| New | +$5.63M |
|
37
ARS Pharmaceuticals
SPRY
$1.08B
| $5.28M | 0.29% |
+500,000
| New | +$5.28M |
|
38
VYNE Therapeutics
VYNE
$8.09M
| $4.67M | 0.26% |
1,394,336
| – | – |
|
39
KALA BIO
KALA
$105M
| $4.19M | 0.23% |
+603,027
| New | +$4.19M |
|
40
GH Research
GHRS
$870M
| $4.15M | 0.23% |
593,043
| – | – |
|
41
Y-mAbs Therapeutics
YMAB
$390M
| $3.33M | 0.18% |
425,000
-1,025,000
| -71% | -$8.03M |
|
|
42
UroGen Pharma
URGN
$896M
| $3.2M | 0.18% |
300,000
-1,250,000
| -81% | -$13.3M |
|
43
Omeros
OMER
$284M
| $2.96M | 0.16% |
+300,000
| New | +$2.96M |
|
44
Stoke Therapeutics
STOK
$1.08B
| $2.8M | 0.15% |
254,161
-173,002
| -41% | -$1.91M |
|
|
45
Biohaven
BHVN
$1.71B
| $2.07M | 0.11% |
55,539
-346,424
| -86% | -$12.9M |
|
|
VERV
46
DELISTED
Verve Therapeutics
VERV
| $1.97M | 0.11% |
350,000
| – | – |
|
|
ARTV
47
Artiva Biotherapeutics, Inc. Common Stock
ARTV
$77.5M
| $1.04M | 0.06% |
103,633
| – | – |
|
48
RAPT Therapeutics
RAPT
$187M
| $316K | 0.02% |
200,000
-296,750
| -60% | -$469K |
|
|
49
AnaptysBio
ANAB
$630M
| – | – |
-342,465
| Closed | -$11.5M |
|
50
Korro Bio
KRRO
$245M
| – | – |
-265,826
| Closed | -$8.88M |
|